The potential value of microseminoprotein-β as a prostate cancer biomarker and therapeutic target

Prostate

Volumn 70, Issue 3, 2010, Pages 333-340

  Whitaker, Hayley C ^a   Warren, Anne Y ^b   Eeles, Rosalind ^c   Kote Jarai, Zsofia ^c   Neal, David E ^a  

^a CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

MSMB; Mutation; Therapeutic

Indexed keywords

AMINO ACID; BETA MICROSEMINOPROTEIN; BIOLOGICAL MARKER; LAMININ RECEPTOR; PROSTATE PROTEIN;

ANIMAL MODEL; APOPTOSIS; CANCER DIAGNOSIS; CARCINOGENESIS; CELL GROWTH; CELL SURFACE; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN SECRETION; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; DISEASE PROGRESSION; GENETIC VARIATION; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 75649121145     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21059     Document Type: Review

References (65)

1. Lilja H, Abrahamsson PA. Three predominant proteins secreted by the human prostate gland. The Prostate 1988;12(1):29-38.
2. Rubenstein M, Guinan PD, McKiel CF, Dubin A. Review of acid phosphatase in the diagnosis and prognosis of prostatic cancers. Clin Physiol Biochem 1988;6(5):241-252.
3. van Dieijen-Visser MP, Delaere KP, Gijzen AH, Brombacher PJ. A comparative study on the diagnostic value of prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) in patients with carcinoma of the prostate gland. Clin Chim Acta (Int J Clin Chem) 1988;174(2):131-140.
4. Turkes A, Nott J, Turkes AO, Griffiths K. Comparison of prostate-specific antigen and prostatic acid phosphatase in the management of prostatic cancer.AmJ Clin Oncol 1988;11(Suppl 2):S77-S79.
5. Taira A, Merrick G, Wallner K, Dattoli M. Reviving the acid phosphatase test for prostate cancer. Oncology (Williston Park, NY) 2007;21(8):1003-1010.
6. Wein AJ, Kavoussi LR, Novick AC, Partin AW. Peters CA. Campbell-Walsh Urology Review Manual 2007. 9th edition. USA: Saunders Elsevier.
7. Dube JY, Frenette G, Paquin R, Chapdelaine P, Tremblay J, Tremblay RR, Lazure C, Seidah N, Chretien M. Isolation from human seminal plasma of an abundant 16-kDa protein originating from the prostate, its identification with a 94-residue peptide originally described as beta-inhibin. J Androl 1987;8(3):182-189.
8. Ulvsback M, LindstromC, Weiber H, Abrahamsson PA, Lilja H, Lundwall A. Molecular cloning of a small prostate protein, known as beta-microsemenoprotein, PSP94 or beta-inhibin, and demonstration of transcripts in non-genital tissues. Biochem Biophys Res Commun 1989;164(3):1310-1315.
9. Kwong J, Xuan JW, Choi HL, Chan PS, Chan FL. PSP94 (or beta-microseminoprotein) is a secretory protein specifically expressed and synthesized in the lateral lobe of the rat prostate. Prostate 2000;42(3):219-229.
10. Thota A, Karajgikar M, Duan W, Gabril MY, Chan FL, Wong YC, Sakai H, Chin JL, Moussa M, Xuan JW. Mouse PSP94 expression is prostate tissue-specific as demonstrated by a comparison of multiple antibodies against recombinant proteins. J Cell Biochem 2003;88(5):999-1011.
11. Imasato Y, Onita T, Moussa M, Sakai H, Chan FL, Koropatnick J, Chin JL, Xuan JW. Rodent PSP94 gene expression is more specific to the dorsolateral prostate and less sensitive to androgen ablation than probasin. Endocrinology 2001;142(5):2138-2146.
12. Gabril MY, Onita T, Ji PG, Sakai H, Chan FL, Koropatnick J, Chin JL, Moussa M, Xuan JW. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model. Gene Therapy 2002;9(23):1589-1599.
13. Gabril M, Xuan J, Moussa M, Dinney CP, Chin JL, Izawa JI. Characterization of initiation of angiogenesis in early stages of prostate adenocarcinoma development and progression in a transgenic murine model. Urology 2004;64(6):1233-1237.
14. Weiber H, Andersson C, Murne A, Rannevik G, Lindstrom C, Lilja H, Fernlund P. Beta microseminoprotein is not a prostate-specific protein. Its identification in mucous glands and secretions. Am J Pathol 1990;137(3):593-603.
15. Baijal-Gupta M, Clarke MW, Finkelman MA, McLachlin CM, Han VK. Prostatic secretory protein (PSP94) expression in human female reproductive tissues, breast and in endometrial cancer cell lines. J Endocrinol 2000;165(2):425-433.
16. Nolet S, St-Louis D, Mbikay M, Chretien M. Rapid evolution of prostatic protein PSP94 suggested by sequence divergence between rhesus monkey and human cDNAs. Genomics 1991; 9(4):775-777.
17. Yanai I, Benjamin H, Shmoish M, Chalifa-Caspi V, Shklar M, Ophir R, Bar-Even A, Horn-Saban S, Safran M, Domany E, Lancet D, Shmueli O. Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification. Bioinformatics (Oxford, England) 2005;21(5):650-659.
18. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, Orth AP, Vega RG, Sapinoso LM, Moqrich A, Patapoutian A, HamptonGM,Schultz PG, Hogenesch JB. Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci USA 2002;99(7):4465-4470.
19. Xuan JW, Wu D, Guo Y, Garde S, Baijal-Gupta M, Chin JL. Analysis of epitope structure of PSP94 (prostate secretory protein of 94 amino acids): (I). Immuno-dominant and immuno-recessive area. J Cell Biochem 1997;65(2):172-185.
20. von der Kammer H, Krauhs E, Aumuller G, Scheit KH. Characterization of a monoclonal antibody specific for prostatic secretory protein of 94 amino acids (PSP94) and development of a two-site binding enzyme immunoassay for PSP94. Clin Chim Acta (Int J Clin Chem) 1990;187(3):207-219.
21. Doctor VM, Sheth AR, Simha MM, Arbatti NJ, Aaveri JP, Sheth NA. Studies on immunocytochemical localization of inhibin-like material in human prostatic tissue: Comparison of its distribution in normal, benign and malignant prostates. Br J Cancer 1986;53(4):547-554.
22. Valtonen-Andre C, Savblom C, Fernlund P, Lilja H, Giwercman A, Lundwall A. beta-Microseminoprotein in serum correlates with the levels in seminal plasma of young, healthy males. J Androl 2008;29(3):330-337.
23. Chan PS, Chan LW, Xuan JW, Chin JL, Choi HL, Chan FL. In situ hybridization study of PSP94 (prostatic secretory protein of 94 amino acids) expression in human prostates. Prostate 1999; 41(2):99-109.
24. Imasato Y, Xuan JW, Sakai H, Izawa JI, Saito Y, Chin JL, Moussa M. PSP94 expression after androgen deprivation therapy: A comparative study with prostate specific antigen in benign prostate and prostate cancer. J Urol 2000;164(5):1819-1824.
25. NamRK, Reeves JR, Toi A, Dulude H, Trachtenberg J, Emami M, Daigneault L, Panchal C, Sugar L, JewettMA,Narod SA.Anovel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol 2006;175(4):1291-1297.
26. Sakai H, Tsurusaki T, Kanda S, Koji T, Xuan JW, Saito Y. Prognostic significance of beta-microseminoprotein mRNA expression in prostate cancer. Prostate 1999;38(4):278-284.
27. Tsurusaki T, Koji T, Sakai H, Kanetake H, Nakane PK, Saito Y. Cellular expression of beta-microseminoprotein (beta-MSP) mRNA and its protein in untreated prostate cancer. Prostate 1998;35(2):109-116.
28. Vanaja DK, Cheville JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003;63(14):3877-3882.
29. Bjartell AS, Al-Ahmadie H, Serio AM, Eastham JA, Eggener SE, Fine SW, Udby L, Gerald WL, Vickers AJ, Lilja H, Reuter VE, Scardino PT. Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res 2007;13(14):4130-4138.
30. Garde SV, Basrur VS, Li L, Finkelman MA, Krishan A, Wellham L, Ben-Josef E, Haddad M, Taylor JD, Porter AT, Tang DG. Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. Prostate 1999;38(2):118-125.
31. Shukeir N, Arakelian A, Kadhim S, Garde S, Rabbani SA. Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res 2003;63(9):2072-2078.
32. Girvan AR, Chang P, van Huizen I, Moussa M, Xuan JW, Stitt L, Chin JL, Yamasaki Y, Izawa JI. Increased intratumoral expression of prostate secretory protein of 94 amino acids predicts for worse disease recurrence and progression after radical prostatectomy in patients with prostate cancer. Urology 2005;65(4): 719-723.
33. Hyakutake H, Sakai H, Yogi Y, Tsuda R, Minami Y, Yushita Y, Kanetake H, Nakazono I, Saito Y. Beta-microseminoprotein immunoreactivity as a new prognostic indicator of prostatic carcinoma. Prostate 1993;22(4):347-355.
34. Reeves JR, Dulude H, Panchal C, Daigneault L, Ramnani DM. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin Cancer Res 2006;12(20 Pt 1):6018-6022.
35. Porter AT, FACRO, Ben-Josef E. Humoral mechanisms in prostate cancer: A role for FSH. Urol Oncol 2001;6(4):131-138.
36. Anahi Franchi N, AvendanoC,MolinaRI, Tissera AD,Maldonado CA, Oehninger S, Coronel CE. beta-Microseminoprotein in human spermatozoa and its potential role in male fertility. Reproduction (Cambridge, England) 2008;136(2):157-166.
37. Yang JP, Baijal-Gupta M, Garde SV, Fraser JE, Finkelman MA, Clarke MW. Identification of binding proteins for PSP94 in human prostate adenocarcinoma cell lines LNCaP and PC-3. Prostate 1998;35(1):11-17.
38. Yang JP, Finkelman MA, Clarke MW. Detection of PSP94 and its specific binding sites in the prostate adenocarcinoma cell line LNCaP. J Urol 1998;160(6 Pt 1):2240-2244.
39. Beke L, Nuytten M, Van Eynde A, Beullens M, Bollen M. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 2007;26(31):4590-4595.
40. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, LaxmanB, Cao X, Jing X, RamnarayananK, Brenner JC,YuJ,Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (New York, NY) 2008;322(5908):1695-1699.
41. Annabi B, Currie JC, Bouzeghrane M, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C,WuJJ, Beliveau R. Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding. Biochem Biophys Res Commun 2006;346(1):358-366.
42. Annabi B, Bouzeghrane M, Currie JC, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Beliveau R. Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling. Anticancer Drugs 2006;17(4):429-438.
43. Annabi B, Bouzeghrane M, Currie JC, Hawkins R, Dulude H, Daigneault L, Ruiz M, Wisniewski J, Garde S, Rabbani SA, Panchal C,WuJJ, Beliveau R.APSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: Implication in tumor metastasis. Clin Exp Metastasis 2005;22(5):429-439.
44. LamyS, Ruiz MT, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ, Annabi B. A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: Implication in tumor angiogenesis. Int J Cancer 2006; 118(9):2350-2358.
45. Wu D, Guo Y, Chambers AF, Izawa JI, Chin JL, Xuan JW. Serum bound forms of PSP94 (prostate secretory protein of 94 amino acids) in prostate cancer patients. J Cell Biochem1999;76(1):71-83.
46. Reeves JR, Xuan JW, Arfanis K, Morin C, Garde SV, Ruiz MT, Wisniewski J, Panchal C, Tanner JE. Identification, purification and characterization of a novel human blood protein with binding affinity for prostate secretory protein of 94 amino acids. Biochem J 2005;385(Pt 1):105-114.
47. Udby L, Lundwall A, Johnsen AH, Fernlund P, Valtonen-Andre C, Blom AM, Lilja H, Borregaard N, Kjeldsen L, Bjartell A. beta-Microseminoprotein binds CRISP-3 in human seminal plasma. Biochem Biophys Res Commun 2005;333(2):555-561.
48. Joshi RR, Jyothi S. Ab initio structure of human seminal plasma prostatic inhibin gives significant insight into its biological functions. J Mol Model 2002;8(2):50-57.
49. Ghasriani H, Teilum K, Johnsson Y, Fernlund P, Drakenberg T. Solution structures of human and porcine beta-microseminoprotein. J Mol Biol 2006;362(3):502-515.
50. GhasrianiH, Fernlund P, Udby L, Drakenberg T. A model of the complex betweenhumanbeta-microseminoprotein and CRISP-3 based onNMRdata. Biochem Biophys ResCommun2009;378(2): 235-239.
51. Xuan JW, Chin JL, Guo Y, Chambers AF, Finkelman MA, Clarke MW.Alternative splicing of PSP94 (prostatic secretory protein of 94 amino acids) mRNA in prostate tissue. Oncogene 1995; 11(6):1041-1047.
52. Ochiai Y, Inazawa J, Ueyama H, Ohkubo I. Humangene for beta-microseminoprotein: Its promoter structure and chromosomal localization. J Biochem 1995;117(2):346-352.
53. Sasaki T, Matsumoto N, Jinno Y, Niikawa N, Sakai H, Kanetake H, Saito Y. Assignment of the human beta-microseminoprotein gene (MSMB) to chromosome 10q11.2. Cytogenet Cell Genet 1996;72(2-3):177-178.
54. Nolet S,MbikayM,ChretienM. Prostatic secretory protein PS P94: Gene organization and promoter sequence in rhesus monkey and human. Biochim Biophys Acta 1991;1089(2):247-249.
55. Ohnuma S, Miura K, Horii A, Fujibuchi W, Kaneko N, Gotoh O, Nagasaki H, Mizoi T, Tsukamoto N, Kobayashi T, Kinouchi M, Okabe M, Sasaki H, Shiiba K, Miyagawa K, Sasaki I. Cancer-associated splicing variants of the CDCA1 and MSMB genes expressed in cancer cell lines and surgically resected gastric cancer tissues. Surgery 2009;145(1):57-68.
56. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA,Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008;40(3):316-321.
57. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hayes RB, Hunter DJ, Chanock SJ. Multiple loci identified in a genomewide association study of prostate cancer. Nat Genet 2008; 40(3):310-315.
58. Kader AK, Sun J, Isaacs SD, Wiley KE, Yan G, Kim ST, Fedor H, Demarzo AM, Epstein JI, Walsh PC, Partin AW, Trock B, Zheng SL, Xu J, Isaacs W. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 2009;69(11):1196-1205.
59. Chang BL, Cramer SD, Wiklund F, Isaacs SD, Stevens VL, Sun J, Smith S, Pruett K, Romero LM, Wiley KE, Kim ST, Zhu Y, Zhang Z, Hsu FC, Turner AR, Adolfsson J, Liu W, Kim JW, Duggan D, Carpten J, Zheng SL, Rodriguez C, Isaacs WB, Gronberg H, Xu J. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet 2009; 18(7):1368-1375.
60. Shukeir N, Arakelian A, Chen G, Garde S, Ruiz M, Panchal C, Rabbani SA. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia. Cancer Res 2004;64(15):5370-5377.
61. Hawkins RE, Daigneault L, Cowan R, Griffiths R, Panchal C, Armstrong A, Fenemore J, Irvine A, Sereda K, Dulude H. Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. Clin Prostate Cancer 2005;4(2):91-99.
62. Lein M, Jung K, Ortel B, Stephan C, Rothaug W, Juchem R, Johannsen M, Deger S, Schnorr D, Loening S, KrellHW.The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 2002;21(13):2089- 2096.
63. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, Cher ML. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002;94(1):17-25.
64. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia (New York, NY) 2004;6(1):1-6.
65. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22(14):2790-2799.